布林佐胺/曲伏前列素(Brinzolamide/Travoprost) - 药物靶点：CA2 x PTGFR_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Travoprost/brinzolamide

靶点

CA2 x PTGFR

作用机制

CA2抑制剂(碳酸酐酶II抑制剂)、PTGFR激动剂(前列腺素FP受体激动剂)

治疗领域

眼部疾病

在研适应症-

非在研适应症

青光眼开角型青光眼

原研机构

Alcon AG

在研机构-

非在研机构

Alcon Research Ltd.Alcon-Couvreur NV

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)终止

特殊审评-

登录后查看时间轴

结构

分子式C26H35F3O6

InChIKeyMKPLKVHSHYCHOC-AHTXBMBWSA-N

CAS号157283-68-6

查看全部结构式(2)

关联

3

项与布林佐胺/曲伏前列素相关的临床试验

NCT00767494 / Terminated临床3期

Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT

The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs. AZOPT dosed BID in patients with open-angle glaucoma or ocular hypertension.

开始日期2008-10-01

申办/合作机构

Alcon Research Ltd.

NCT00527501 / Completed临床2期

IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension

The purpose of this study is to compare the safety and IOP-lowering efficacy of a fixed combination of Travoprost/Brinzolamide Ophthalmuc Suspension dosed BID and QD, to TRAVATAN dosed QD and a Vehicle dosed BID in patients with open-angle glaucoma or ocular hypertension.

开始日期2007-08-01

申办/合作机构

Alcon Research Ltd.

NCT00372827 / Completed临床4期

Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension

The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.

开始日期2004-02-01

申办/合作机构

Alcon Research Ltd.

100 项与布林佐胺/曲伏前列素相关的临床结果

登录后查看更多信息

100 项与布林佐胺/曲伏前列素相关的转化医学

登录后查看更多信息

100 项与布林佐胺/曲伏前列素相关的专利（医药）

登录后查看更多信息

100 项与布林佐胺/曲伏前列素相关的药物交易

登录后查看更多信息